A US FDA green light for Karyopharm Therapeutics Inc.'s selinexor seemed highly unlikely following a February advisory committee meeting, but the company may have a reason to hope for approval, as the agency delayed the user fee goal date by three months following the submission of additional data.
Also landing a three-month user fee extension was Bavarian Nordic AS’s smallpox vaccine MVA-BN, for which the sponsor similarly...